Kenvue Inc. (KVUE)
| Market Cap | 32.85B -28.5% |
| Revenue (ttm) | 15.29B -0.1% |
| Net Income | 1.62B +53.6% |
| EPS | 0.84 +52.3% |
| Shares Out | 1.92B |
| PE Ratio | 20.37 |
| Forward PE | 14.14 |
| Dividend | $0.83 (4.85%) |
| Ex-Dividend Date | May 13, 2026 |
| Volume | 22,136,972 |
| Open | 17.24 |
| Previous Close | 17.19 |
| Day's Range | 16.98 - 17.36 |
| 52-Week Range | 14.02 - 24.36 |
| Beta | 0.52 |
| Analysts | Buy |
| Price Target | 19.45 (+13.68%) |
| Earnings Date | May 7, 2026 |
About KVUE
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral a... [Read more]
Financial Performance
In 2025, Kenvue's revenue was $15.12 billion, a decrease of -2.14% compared to the previous year's $15.46 billion. Earnings were $1.47 billion, an increase of 42.72%.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for KVUE stock is "Buy." The 12-month stock price target is $19.45, which is an increase of 13.68% from the latest price.
News
Kenvue beats first-quarter estimates amid pending acquisition by Kimberly-Clark
Tylenol-maker Kenvue on Thursday beat Wall Street estimates for first-quarter revenue and profit helped by strong sales in its skin health and beauty brands.
Kenvue reports Q1 adjusted EPS 32c, consensus 26c
Reports Q1 revenue $3.91B, consensus $3.85B. “Our year is off to an encouraging start, as our continued efforts to strengthen the business and sharpen execution resulted in delivering net and…
Kenvue Reports First Quarter 2026 Results
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced financial results for the fiscal first quarter ended March 29, 2026. “Our year is off to an encouraging start, as our continued ...
Kenvue Declares Quarterly Cash Dividend
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced that its Board of Directors declared a quarterly dividend of $0.2075 per share on its common stock. The quarterly dividend is pa...
Kenvue to Announce First Quarter 2026 Results on May 7, 2026
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) will announce its first quarter 2026 financial results before the market opens on May 7, 2026. Due to the pending transaction with Kimberly-Clar...
Kimberly-Clark Details Structure, Leadership Team Following Kenvue Deal
The combined company, which will include consumer brands such as Kleenex tissues and Huggies diapers as well as over-the-counter products including Tylenol and Listerine, will operate under four geogr...
Kimberly-Clark retains Urdaneta as CFO of combined company after $40-billion Kenvue deal
Kimberly-Clark on Wednesday said its chief financial officer, Nelson Urdaneta, will become the finance chief of the combined company it will create after completing its $40-billion acquisition of Ty...
Kimberly-Clark announces organizational structure after acquisition of Kenvue
Kimberly-Clark (KMB) announced the organizational structure and key leadership that will become effective upon completion of its pending acquisition of Kenvue (KVUE). After close, the combined company...
Kimberly-Clark Announces Post-Closing Organizational Structure and Identifies Key Leadership
DALLAS, April 15, 2026 /PRNewswire/ -- Kimberly‑Clark Corporation (NASDAQ: KMB) today announced the organizational structure and key leadership that will become effective upon completion of its pendin...
Kenvue price target lowered to $19 from $20 at Citi
Citi lowered the firm’s price target on Kenvue (KVUE) to $19 from $20 and keeps a Neutral rating on the shares. The firm adjusted targets in the beverages, household and…
Kenvue price target lowered to $18 from $19 at Barclays
Barclays lowered the firm’s price target on Kenvue (KVUE) to $18 from $19 and keeps an Equal Weight rating on the shares. The firm adjusted targets in the consumer staples…
Tylenol in pregnancy not linked with autism, Danish study finds
The use of Tylenol by women during pregnancy was not associated with autism in their children, according to results of a nationwide study in Denmark published on Monday.
Kenvue Inc call volume above normal and directionally bullish
Bullish option flow detected in Kenvue (KVUE) Inc with 4,504 calls trading, 1.3x expected, and implied vol increasing over 6 points to 30.83%. Jun-26 18 calls and May-26 18 calls…
Kenvue price target lowered to $18 from $19 at UBS
UBS lowered the firm’s price target on Kenvue (KVUE) to $18 from $19 and keeps a Neutral rating on the shares. The firm thinks Q1 results for much of the…
Tylenol use among women dropped after Trump tied it to autism
Tylenol use among pregnant women fell after U.S. President Donald Trump linked autism to the over-the-counter pain relief medicine, according to an analysis of U.S. emergency room prescribing patterns...
Kenvue price target raised to $19 from $18 at Barclays
Barclays analyst Lauren Lieberman raised the firm’s price target on Kenvue (KVUE) to $19 from $18 and keeps an Equal Weight rating on the shares. The firm updated the company’s…
Judge spurns Kenvue bid to dismiss Texas lawsuit over Tylenol, Reuters reports
Judge LeAnn Rafferty in Panola County, Texas dismissed Kenvue’s (KVUE) bid to throw out a lawsuit by state Attorney General Ken Paxton claiming the company falsely marketed Tylenol by concealing…
Judge rejects Kenvue bid to dismiss Texas lawsuit over Tylenol
A Texas judge on Thursday rejected Kenvue's bid to dismiss a lawsuit by that state's Attorney General Ken Paxton accusing the company of concealing autism and other risks to children when pregnant wom...
Kenvue Inc call volume above normal and directionally bullish
Bullish option flow detected in Kenvue (KVUE) Inc with 31,583 calls trading, 2x expected, and implied vol increasing almost 9 points to 32.75%. Feb-26 19 calls and Mar-26 19 calls…
Kenvue rumor highlighted in Betaville blog
A rumor regarding Kenvue (KVUE) was highlighted in Ben Harrington’s M&A-focused Betaville blog, contacts tell The Fly.
Kenvue price target raised to $19 from $17 at UBS
UBS raised the firm’s price target on Kenvue (KVUE) to $19 from $17 and keeps a Neutral rating on the shares. Kenvue posted a better than feared Q4, the analyst…
Kenvue price target raised to $18 from $17 at Canaccord
Canaccord raised the firm’s price target on Kenvue (KVUE) to $18 from $17 and keeps a Hold rating on the shares. The firm said they reported a beat on the…
Kenvue price target raised to $20 from $18 at Citi
Citi raised the firm’s price target on Kenvue (KVUE) to $20 from $18 and keeps a Neutral rating on the shares.
Kenvue to Cut 3.5% of Workforce Ahead of Kimberly-Clark Deal
The job cuts are part of a restructuring plan to optimize its operating model and drive operational efficiencies, the company said.